Cargando…

Insights of different analytical approaches for estimation of budesonide as COVID-19 replication inhibitor in its novel combinations: green assessment with AGREE and GAPI approaches

Simple, direct, rapid, and sensitive HPLC and spectrophotometric methods were established for simultaneous estimation of a novel combination of budesonide and azelastine (BUD/AZL) in their laboratory-prepared mixture and dosage form according to the medicinally recommended ratio 1:4.28. Budesonide i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammouda, Mohammed E. A., El-Masry, Amal A., El-Ashry, Saadia M., El-Wasseef, Dalia R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013279/
https://www.ncbi.nlm.nih.gov/pubmed/36918985
http://dx.doi.org/10.1186/s13065-023-00936-z
_version_ 1784906780173664256
author Hammouda, Mohammed E. A.
El-Masry, Amal A.
El-Ashry, Saadia M.
El-Wasseef, Dalia R.
author_facet Hammouda, Mohammed E. A.
El-Masry, Amal A.
El-Ashry, Saadia M.
El-Wasseef, Dalia R.
author_sort Hammouda, Mohammed E. A.
collection PubMed
description Simple, direct, rapid, and sensitive HPLC and spectrophotometric methods were established for simultaneous estimation of a novel combination of budesonide and azelastine (BUD/AZL) in their laboratory-prepared mixture and dosage form according to the medicinally recommended ratio 1:4.28. Budesonide is an important inhalation corticosteroid that plays a vital role in the inhibition of COVID-19 replication and cytokine production. The first chromatographic method was created for the simultaneous estimation of BUD epimers in the presence of AZL with excellent efficiency in a relatively short chromatographic run (< 9 min). The separation of BUD epimers with AZL was carried out on a C(18) column using acetonitrile: phosphate buffer of pH 3.5 adjusted by 0.2 M orthophosphoric acid (40:60, v/v) as a mobile phase, UV detection at 230 nm and a flow rate of regulated at 2 mL/min. Besides, three spectrophotometric methods were applied for the simultaneous determination of the provided mixture adopting zero order, first order derivative, and ratio first derivative approaches. The Zero-order spectrophotometry was used for the determination of AZL in presence of BUD, where BUD shows no absorbance at 290 nm. The first derivative amplitude at 265 nm ((1)D(265)) (zero-crossing of AZL) and the ratio of first derivative amplitudes at 270 nm ((1)DD(270)) using 10.0 µg mL(−1) AZL as divisor was chosen for the simultaneous determination of BUD in the presence of AZL in the binary mixture. The proposed methods were found to be rectilinear in the concentration range of (0.4–40.0 µg mL(−1)) and (0.05–40.0 µg mL(−1)) for BUD and AZL, respectively in the HPLC method. Whereas the concentration range for AZL in the zero-order method was (1.0–35.0 µg mL(−1)) and for BUD in the first derivative and ratio derivative method was (6.0–20.0 µg mL(−1)). Validation of the suggested approaches according to the ICH criteria was performed. Furthermore, to ensure the proposed approaches' greenness, The AGREE and GAPI metrics were utilized, and the afforded results revealed an excellent greenness of the proposed approaches. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13065-023-00936-z.
format Online
Article
Text
id pubmed-10013279
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-100132792023-03-14 Insights of different analytical approaches for estimation of budesonide as COVID-19 replication inhibitor in its novel combinations: green assessment with AGREE and GAPI approaches Hammouda, Mohammed E. A. El-Masry, Amal A. El-Ashry, Saadia M. El-Wasseef, Dalia R. BMC Chem Research Simple, direct, rapid, and sensitive HPLC and spectrophotometric methods were established for simultaneous estimation of a novel combination of budesonide and azelastine (BUD/AZL) in their laboratory-prepared mixture and dosage form according to the medicinally recommended ratio 1:4.28. Budesonide is an important inhalation corticosteroid that plays a vital role in the inhibition of COVID-19 replication and cytokine production. The first chromatographic method was created for the simultaneous estimation of BUD epimers in the presence of AZL with excellent efficiency in a relatively short chromatographic run (< 9 min). The separation of BUD epimers with AZL was carried out on a C(18) column using acetonitrile: phosphate buffer of pH 3.5 adjusted by 0.2 M orthophosphoric acid (40:60, v/v) as a mobile phase, UV detection at 230 nm and a flow rate of regulated at 2 mL/min. Besides, three spectrophotometric methods were applied for the simultaneous determination of the provided mixture adopting zero order, first order derivative, and ratio first derivative approaches. The Zero-order spectrophotometry was used for the determination of AZL in presence of BUD, where BUD shows no absorbance at 290 nm. The first derivative amplitude at 265 nm ((1)D(265)) (zero-crossing of AZL) and the ratio of first derivative amplitudes at 270 nm ((1)DD(270)) using 10.0 µg mL(−1) AZL as divisor was chosen for the simultaneous determination of BUD in the presence of AZL in the binary mixture. The proposed methods were found to be rectilinear in the concentration range of (0.4–40.0 µg mL(−1)) and (0.05–40.0 µg mL(−1)) for BUD and AZL, respectively in the HPLC method. Whereas the concentration range for AZL in the zero-order method was (1.0–35.0 µg mL(−1)) and for BUD in the first derivative and ratio derivative method was (6.0–20.0 µg mL(−1)). Validation of the suggested approaches according to the ICH criteria was performed. Furthermore, to ensure the proposed approaches' greenness, The AGREE and GAPI metrics were utilized, and the afforded results revealed an excellent greenness of the proposed approaches. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13065-023-00936-z. Springer International Publishing 2023-03-14 /pmc/articles/PMC10013279/ /pubmed/36918985 http://dx.doi.org/10.1186/s13065-023-00936-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hammouda, Mohammed E. A.
El-Masry, Amal A.
El-Ashry, Saadia M.
El-Wasseef, Dalia R.
Insights of different analytical approaches for estimation of budesonide as COVID-19 replication inhibitor in its novel combinations: green assessment with AGREE and GAPI approaches
title Insights of different analytical approaches for estimation of budesonide as COVID-19 replication inhibitor in its novel combinations: green assessment with AGREE and GAPI approaches
title_full Insights of different analytical approaches for estimation of budesonide as COVID-19 replication inhibitor in its novel combinations: green assessment with AGREE and GAPI approaches
title_fullStr Insights of different analytical approaches for estimation of budesonide as COVID-19 replication inhibitor in its novel combinations: green assessment with AGREE and GAPI approaches
title_full_unstemmed Insights of different analytical approaches for estimation of budesonide as COVID-19 replication inhibitor in its novel combinations: green assessment with AGREE and GAPI approaches
title_short Insights of different analytical approaches for estimation of budesonide as COVID-19 replication inhibitor in its novel combinations: green assessment with AGREE and GAPI approaches
title_sort insights of different analytical approaches for estimation of budesonide as covid-19 replication inhibitor in its novel combinations: green assessment with agree and gapi approaches
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013279/
https://www.ncbi.nlm.nih.gov/pubmed/36918985
http://dx.doi.org/10.1186/s13065-023-00936-z
work_keys_str_mv AT hammoudamohammedea insightsofdifferentanalyticalapproachesforestimationofbudesonideascovid19replicationinhibitorinitsnovelcombinationsgreenassessmentwithagreeandgapiapproaches
AT elmasryamala insightsofdifferentanalyticalapproachesforestimationofbudesonideascovid19replicationinhibitorinitsnovelcombinationsgreenassessmentwithagreeandgapiapproaches
AT elashrysaadiam insightsofdifferentanalyticalapproachesforestimationofbudesonideascovid19replicationinhibitorinitsnovelcombinationsgreenassessmentwithagreeandgapiapproaches
AT elwasseefdaliar insightsofdifferentanalyticalapproachesforestimationofbudesonideascovid19replicationinhibitorinitsnovelcombinationsgreenassessmentwithagreeandgapiapproaches